Clinical Studies of Ivermectin was broadcast on Twitter today by the inventor of the mRNA vaccine, Dr. Robert Malone.
One month after the declaration of the pandemic, countries such as Iraq, Egypt, Iran, and India began to register clinical trials with the US clinical trial registration site ClinicalTrials.gov and the WHO’s clinical trial registration platform. The publication of the results of the first clinical trial of ivermectin for COVID-19 in the world was an observational study conducted at four related hospitals in South Florida, USA. The mortality rate of 173 patients in the ivermectin group was 15.0%, which was significantly (p＝0.03) superior to 25.2% of 107 patients in the control group. This result was published as a medRxiv preprint on the 6th of June 2020, but its value was not recognized at the time because it had not yet been peer reviewed. Following peer review, it was published without any changes in the prestigious journal Chest on the 13th of October.
Since then, numerous clinical trials have been conducted in various countries around the world. As of the 30th of January 2021, a total of 91 trials in 27 countries has been recorded at these registration sites. There are 43 trials in phase 3 and 27 trials in phase 2, along with 17 observational studies. This includes 80 trials being conducted for therapeutic purposes and 11 for the purpose of preventing the onset of disease in close contacts and healthcare professionals.
Ivermectin-studyRobert W. Malone, M.D., M.S.
Dr. Malone is the discoverer of in-vitro and in-vivo RNA transfection and the inventor of mRNA vaccines, while he was at the Salk Institute in 1988. His research was continued at Vical in 1989, where the first in-vivo mammalian experiments were designed by him. The mRNA, constructs, reagents were developed at the Salk institute and Vical by Dr. Malone. The initial patent disclosures were written by Dr. Malone in 1988-1989. Dr. Malone was also an inventor of DNA vaccines in 1988 and 1989. This work results in over 10 patents and numerous publications, yielding about 7000 citations for this work. Dr. Malone was also an inventor of DNA vaccines in 1988 and 1989. https://www.youtube.com/embed/HgZGxOSKdOY?wmode=opaque&enablejsapi=1
Dr. Malone has extensive research and development experience in the areas of pre-clinical discovery research, clinical trials, vaccines, gene therapy, bio-defense, and immunology. He has over twenty years of management and leadership experience in academia, pharmaceutical and biotechnology industries, as well as in governmental and non-governmental organizations.
Dr. Malone specializes in clinical research, medical affairs, regulatory affairs, project management, proposal management (large grants and contracts), vaccines and biodefense. This includes writing, developing, reviewing and managing vaccine, bio-threat and biologics clinical trials and clinical development strategies. He has been involved in developing, designing, and providing oversight of approximately forty phase 1 clinical trials and twenty phase 2 clinical trials, as well as five phase 3 clinical trials. He has served as medical director/medical monitor on approximately forty phase 1 clinical trials, and on twenty phase 2 clinical trials, including those run at vaccine-focused Clinical Research Organizations. His proposal development work has yielded clients billions of dollars.
Scientifically trained at UC Davis, UC San Diego, and at the Salk Institute Molecular Biology and Virology laboratories, Dr. Malone is an internationally recognized scientist (virology, immunology, molecular biology) and is known as one of the original inventors of mRNA vaccination and DNA Vaccination. His discoveries in mRNA non viral delivery systems are considered the key to the current COVID-19 vaccine strategies. Dr. Malone holds numerous fundamental domestic and foreign patents in the fields of gene delivery, delivery formulations, and vaccines.
He received his medical training at Northwestern University (MD) and Harvard University (Clinical Research Post Graduate) medical school, and in Pathology at UC Davis.
Dr. Malone has close to 100 peer-reviewed publications and published abstracts and has over 11,477 citations of his peer reviewed publications, as verified by Google Scholar. His google scholar ranking is “outstanding” for impact factors. He has been an invited speaker at over 50 conferences, has chaired numerous conferences and he has sat on or served as chairperson on numerous NIAID and DoD study sections.
0 Comments for “Global trends in clinical studies of Ivermectin in COVID-19”